Immunogenicity of Yeast-derived Hepatitis B Vaccine from Two Different Producers

Overview

Journal Epidemiol Infect

Publisher Cambridge University Press

Specialties Infectious Diseases
Public Health

Date 1990 Feb 1

PMID 2137785

Citations 6

Authors

J C SIEBKE

S S Froland

M DeGre

Affiliations

Soon will be listed here.

Abstract

The immunogenicity and reactogenicity of two preparations of yeast-derived hepatitis B vaccines were compared in healthy adult populations. The two groups were vaccinated in parallel, but they were not matched for age and sex. All subjects seroconverted, and 9 months after the first vaccine dose, all had anti HBs titres of at least 10 IU/l. The anti-HBs titres were higher in the group of subjects given 20 micrograms vaccine antigen made by Smith Kline & RIT (GMT 2943 at 9 months) compared to those who received 10 micrograms of vaccine made by Merck, Sharp & Dohme (GMT 729 at 9 months). Adverse effects were recorded in 32.0 and 44.7% of the participants, but these were limited to minor local and general reactions. In the present study both preparations were safe and efficient.

Citing Articles

Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.

Cid R, Bolivar J Biomolecules. 2021; 11(8).

PMID: 34439738 PMC: 8394948. DOI: 10.3390/biom11081072.

Factors influencing immunologic response to hepatitis B vaccine in adults.

Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C Sci Rep. 2016; 6:27251.

PMID: 27324884 PMC: 4914839. DOI: 10.1038/srep27251.

Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens.

Liljeroos L, Malito E, Ferlenghi I, Bottomley M J Immunol Res. 2015; 2015:156241.

PMID: 26526043 PMC: 4615220. DOI: 10.1155/2015/156241.

From empiricism to rational design: a personal perspective of the evolution of vaccine development.

De Gregorio E, Rappuoli R Nat Rev Immunol. 2014; 14(7):505-14.

PMID: 24925139 PMC: 7096907. DOI: 10.1038/nri3694.

Reducing alcohol consumption. Comparing three brief methods in family practice.

McIntosh M, Leigh G, Baldwin N, Marmulak J Can Fam Physician. 1997; 43:1959-62, 1965-7.

PMID: 9386883 PMC: 2255191.

References

Milne A, Brawner T, Dumbill P, Kawachi I, Pearce N . Comparison of the immunogenicity of reduced doses of two recombinant DNA hepatitis B vaccines in New Zealand children. J Med Virol. 1989; 27(3):264-7. DOI: 10.1002/jmv.1890270314. View

SZMUNESS W, Stevens C, Zang E, Harley E, Kellner A . A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981; 1(5):377-85. DOI: 10.1002/hep.1840010502. View

Valenzuela P, Medina A, Rutter W, Ammerer G, Hall B . Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982; 298(5872):347-50. DOI: 10.1038/298347a0. View

Harford N, Cabezon T, Crabeel M, Simoen E, Rutgers A, de Wilde M . Expression of hepatitis B surface antigen in yeast. Dev Biol Stand. 1983; 54:125-30. View

Jilg W, Lorbeer B, Schmidt M, Wilske B, Zoulek G, Deinhardt F . Clinical evaluation of a recombinant hepatitis B vaccine. Lancet. 1984; 2(8413):1174-5. DOI: 10.1016/s0140-6736(84)92740-5. View

Walgate R . Hepatitis B. Taiwan plans mass vaccination. Nature. 1984; 312(5991):190. DOI: 10.1038/312190b0. View

Davidson M, Krugman S . Immunogenicity of recombinant yeast hepatitis B vaccine. Lancet. 1985; 1(8420):108-9. DOI: 10.1016/s0140-6736(85)92000-8. View

Hadler S, Francis D, MAYNARD J, THOMPSON S, Judson F, Echenberg D . Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986; 315(4):209-14. DOI: 10.1056/NEJM198607243150401. View

FRISCH-NIGGEMEYER W, Ambrosch F, Hofmann H . The assessment of immunity against hepatitis B after vaccination. J Biol Stand. 1986; 14(3):255-8. DOI: 10.1016/0092-1157(86)90011-9. View

10.

Hollinger F . Hepatitis B vaccines--to switch or not to switch. JAMA. 1987; 257(19):2634-6. View

11.

Goudeau A, Denis F, Mounier M, Dubois F, Klein J, Godefroy A . Comparative multicentre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers. Postgrad Med J. 1987; 63 Suppl 2:125-8. View

12.

Ambrosch F, FRISCH-NIGGEMEYER W, Kremsner P, Kunz C, Andre F, Safary A . Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgrad Med J. 1987; 63 Suppl 2:129-35. View

13.

Bergamini F, Zanetti A . Immunogenicity of yeast-derived hepatitis B vaccines in young adults. Postgrad Med J. 1987; 63 Suppl 2:137-8. View

14.

Odaka N, Eldred L, Cohn S, Munoz A, Fields H, Fox R . Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. JAMA. 1988; 260(24):3635-7. View